Exelixis

Exelixis ROA

The Return on Assets (ROA) of Exelixis (EXEL) as of Oct 27, 2026 is 27.51 %. In the previous year, Return on Assets (ROA) was 17.68 % — a change of 55.58% (higher).

ROA

27.51 %

YoY

55.58%

Last updated:

In 2025, Exelixis's return on assets (ROA) was 27.51 %, a 55.58% increase from the 17.68 % ROA in the previous year.

The Exelixis ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
48.52 USD
Jan 1, 2019
17.02 USD
Jan 1, 2020
5.23 USD
Jan 1, 2021
8.83 USD
Jan 1, 2022
5.93 USD
Jan 1, 2023
7.06 USD
Jan 1, 2024
17.68 USD
Jan 1, 2025
27.51 USD
The Exelixis ROA history
YEARROAYoY
27.51 %+55.58%
17.68 %+150.44%
7.06 %+18.98%
5.93 %-32.80%
8.83 %+68.87%
5.23 %-69.28%
17.02 %-64.91%
48.52 %+106.15%
23.54 %-300.27%
-11.75 %-76.99%
-51.07 %-37.63%
-81.88 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Exelixis Stock analysis

What does Exelixis do? Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis is one of the most popular companies on Eulerpool.

ROA Details

Understanding Exelixis's Return on Assets (ROA)

Exelixis's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Exelixis's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Exelixis's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Exelixis’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Exelixis stock

Return on Assets (ROA) of Exelixis is 27.51 % in 2025.

Return on Assets (ROA) of Exelixis changed from 17.68 % to 27.51 %, representing a 55.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Exelixis since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Exelixis with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Exelixis

All Key Metrics — Exelixis